Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Guidez

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
La Revue De Medecine Interne|September 21, 2013
[Smoldering multiple myeloma]G Fouquet, S Guidez, C Herbaux, et al.
Annals of Hematology|May 27, 2020
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry studyT Systchenko, G Defossez, S Guidez, et al.
La Revue De Medecine Interne|January 19, 2015
[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]G Fouquet, K Amouzou, L Renaud, et al.
La Revue De Medecine Interne|August 11, 2015
[Pomalidomide for multiple myeloma]G Fouquet, M Macro, O Decaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2024
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]T M Kim, M Taszner, S Novelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2024
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphomaT M Kim, M Taszner, S Novelli, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
La Revue De Medecine Interne|September 21, 2013
[Smoldering multiple myeloma]G Fouquet, S Guidez, C Herbaux, et al.
Annals of Hematology|May 27, 2020
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry studyT Systchenko, G Defossez, S Guidez, et al.
La Revue De Medecine Interne|January 19, 2015
[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]G Fouquet, K Amouzou, L Renaud, et al.
La Revue De Medecine Interne|August 11, 2015
[Pomalidomide for multiple myeloma]G Fouquet, M Macro, O Decaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2024
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]T M Kim, M Taszner, S Novelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2024
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphomaT M Kim, M Taszner, S Novelli, et al.
Pageof 1